IMPORTANCE Poor adherence to recommended preventive asthma medications is common, leading to preventable morbidity. We developed the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program to build on school-based supervised therapy programs by incorporating telemedicine at school to overcome barriers to preventive asthma care.
I nhaled corticosteroids are the most effective long-term therapy for patients with asthma, 1 and guidelines recommend that preventive medications be used daily for all patients with persistent symptoms.
2 However, many children with persistent asthma do not receive preventive medications, [3] [4] [5] and minority children living in poverty are at highest risk of inadequate therapy. [6] [7] [8] [9] In addition, many children who are prescribed a preventive medication do not achieve optimal control, at least in part because of poor adherence 10 and a lack of appropriate follow-up care. 11 Thus, efforts to improve the delivery of preventive asthma care are warranted.
We have a long-standing partnership with the Rochester City School District to develop programs for urban schoolaged children with asthma. Our original School-Based Asthma Therapy study 12, 13 tested directly observed therapy (DOT) of preventive asthma medications in school for children aged 3 to 10 years. By supervising daily medication administration in school, we could ensure that children consistently received their medications, at least on days they attended school. In a randomized clinical trial, we found that children receiving preventive medications at school had more symptomfree days (SFDs) and fewer exacerbations compared with a group receiving usual care. 13 However, we found that the program was difficult to maintain in its original design because the coordination of the child's assessments, medication prescription, and facilitation of medication delivery through school required an unsustainable effort by the research team. 14 We developed the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program in hopes of achieving sustainability. The SB-TEAM program expands our successful school partnership by integrating 2 systems of care to ensure access to guideline-based preventive asthma treatment. The SB-TEAM program uses school-based DOT of preventive asthma medications to enhance medication adherence, as well as telemedicine to ensure access to appropriate asthma assessments, preventive medication prescription, and follow-up care. Telemedicine allows clinicians to provide assessment and consultation through remote audiovisual technology and removes barriers to accessing care by enabling children to be seen by a clinician without making a trip to their physician's office. [15] [16] [17] [18] [19] [20] Our primary hypothesis was that children receiving the SB-TEAM intervention would have more SFDs postintervention compared with children in an enhanced usual care (eUC) group.
Methods

Participants
We recruited 400 children from 49 schools in Rochester, New York, over 4 consecutive school years (2012) (2013) (2014) (2015) (2016) . Eligibility requirements included physician-diagnosed asthma with persistent symptoms or poor control based on National Heart, Lung, and Blood Institute guidelines, 2 age of 3 to 10 years, and enrollment in the Rochester City School District. Children and families were ineligible if they were unable to speak English, did not have access to a telephone for follow-up, or had other significant medical conditions (eg, congenital heart disease or cystic fibrosis) that might interfere with assessments. The University of Rochester institutional review board approved the study, and written informed consent was obtained from all caregivers and vocal informed assent from all children 7 years and older. The trial protocol can be found in Supplement 1.
Procedures
Screening for eligibility occurred at the start of each school year. School nurses and study team members identified children with asthma from school health records and conducted a telephone survey with the child's caregiver to assess eligibility. Enrollment occurred in a rolling fashion during the first 4 months of school in an attempt to enroll children prior to the onset of peak asthma season. Details of the methods have been reported.
14 Following eligibility screening, a home visit was conducted to obtain informed consent from caregivers and assent from children 7 years and older. The baseline evaluation included an assessment of asthma symptoms, caregiver depression, 21 exposure to secondhand smoke, 22 and standard family and health history. We gave each caregiver an asthma symptom diary to track the child's symptoms throughout the school year. We also obtained a saliva sample from each child to measure smoke exposure through the biomarker cotinine. 23 , 24 Lastly, we obtained fractional exhaled nitric oxide (FeNO) measurements using the NIOX VERO monitor (Circassia) to objectively measure airway inflammation. 25 Following baseline assessment, each child was randomly assigned to either the SB-TEAM group or the eUC group. A permutated block design was used to ensure balance in groups over time. Randomization was stratified by the use of a preventive medication at baseline and was developed by the biostatistician. The interviewer called the study coordinator for treatment assignment. All families received an educational packet that included basic asthma information, smoking cessation resources, and local asthma resources. Once randomized, primary care physicians (PCPs) received a symptom report from the screening assessment and notification of the child's enrollment. The intervention continued for 1 school year. year (within 2 weeks of baseline) for an initial asthma assessment and to determine the starting medication to be administered through DOT at school. Caregivers were invited to join the child at school for the visit.
Details of the telemedicine intervention have been described.
14 Briefly, a clinical telemedicine assistant who already worked in the school district brought a mobile telemedicine unit to the school and met with children, entered information regarding their symptoms and triggers, and uploaded physical examination data (ie, images, height and weight data, and breath sounds). This information was securely stored in the telemedicine virtual waiting room until a clinician completed the visit from their office (within 3 days), or the visit was done in real-time using videoconferencing. The telemedicine clinician then contacted the child's caregiver via telephone (or videoconference) to discuss the child's asthma, develop a treatment plan, and provide education and referrals as needed.
Telemedicine visits used a standard asthma template to assess impairment and risk, and reimbursement requests were submitted to the child's insurance, similar to a standard asthma visit. We scheduled telemedicine visits with the child's primary care practice when possible. If the child's practice did not perform telemedicine visits, we used available clinicians from the University of Rochester and relayed information about the child's visit back to PCPs. Clinicians were offered brief training sessions at the beginning of each intervention year, which included an overview of the burden of asthma, the newest guideline recommendations, and tips for delivering guideline-based care.
All of the children in the study had persistent asthma or poor control on enrollment and thus required a daily preventive asthma medication. We requested that clinicians send prescriptions to pharmacies that provide delivery services and requested that 2 canisters of medication (with a spacer and mask, as appropriate)-1 for home doses on weekends and days the child did not attend school and 1 for school-based DOT-be delivered. When necessary, we requested early refill overrides from insurers to ensure payment for 2 canisters. Most children received once-daily dosing 26 to allow for medication administration during school hours; if more frequent dosing was needed, additional doses were given at home. Follow-up telemedicine assessments occurred 4 to 6 weeks after the start of DOT and again 4 to 6 weeks later. The follow-up visits allowed for an assessment of the child's asthma control once they were established on DOT and an opportunity to inquire about triggers or comorbid conditions that might interfere with an optimal treatment response. Clinicians were encouraged to deliver asthma education and make guidelinebased medication adjustments (or specialist referral) for children who continued to have poor control. Changes to medications were implemented as DOT through school.
The study team nurse reviewed telemedicine visits to ensure efficient completion of guideline-based care, including appropriate prescription of preventive medications. Any discrepancies were relayed back to the telemedicine clinician with specific recommendations.
Two weeks prior to the close of the study, we notified both PCPs and families that children receiving preventive medications at school no longer would receive medications through the study. While a step-down in therapy is appropriate for many children in the summertime, PCPs were encouraged to provide ongoing medication management as needed.
eUC Comparison Condition
Similar to children in the SB-TEAM group, children in the eUC group received a guideline-based symptom assessment, a recommendation for preventive medications, and asthma education materials. After randomization, we sent a symptom report to the PCP with guideline-based recommendations for care. We provided systematic feedback to families and PCPs at the same intervals as the SB-TEAM telemedicine visits and recommended that caregivers schedule follow-up visits. While participants were not blinded to group allocation, they were told that they were randomly assigned to 2 different ways of approaching asthma management.
Outcomes Assessment
We assessed outcomes for children in both groups by telephone interviews with caregivers and review of medical and school records. An independent team blinded to group allocation collected follow-up data every other month, and a final follow-up home visit was conducted at the end of the school year. Caregivers received $25 gift cards following baseline assessment, $20 after each telephone survey, and $50 at study completion. There was no payment for participation in the intervention components.
The primary outcome was SFDs postintervention (after 4 months, 6 months, and at final follow-up). Caregivers reported the number of days their child experienced no symptoms of asthma (24 hours with no coughing, wheezing, or shortness of breath, and no need for rescue medications) over the prior 2 weeks.
12 They were referred to their symptom diaries to assist with recollection. Secondary symptom measures included the number of days and nights with asthma symptoms, days needing rescue medications, and days with limited activity, measured by 2-week recall. Parents were asked to report any health care utilization, including urgent (acute, emergency department, or hospitalization) and nonurgent (primary or specialist) visits for asthma care. Medical records were reviewed for 20% of the sample to confirm health care utilization; all documented visits were also reported by caregivers.
We measured caregiver quality of life using the validated Pediatric Asthma Caregiver's Quality of Life Questionnaire.
27
School absenteeism because of asthma was assessed by caregiver report. We also measured FeNO levels at the final assessment. 25 
Statistical Analysis
We estimated the power to detect the smallest clinically significant difference in mean SFDs postintervention between the SB-TEAM and eUC groups, accounting for repeated measures. Based on prior data, we estimated the pooled standard deviation of SFD at 2.8 and within-participant correlation at 0.3. 13 A sample of 400 obtains greater than 90% power to detect a difference of 0.8 SFD per 2 weeks or greater (2-sided P < .05). Analyses were multivariable modified intention to treat, including all participants with postintervention data.
28
Generalized estimating equation (GEE) models were fitted with repeated asthma outcomes (at 4 months, 6 months, and final assessment) as dependent variables and treatment group as the independent variable after controlling for baseline symptoms and use of preventive medications. 29 An unstructured covariance matrix was specified. We estimated the withinschool intraclass correlation coefficient and found little clustering effect (intraclass correlation coefficient range, <0.01-0.02); therefore, school was not included. We also tested the interaction of treatment by time and specified contrasts to test the treatment effect at each time point. For binary outcomes, a binomial error and logitlink function were specified. Changes in FeNO level and quality of life were compared using 2-sample t tests. We examined missing data patterns and performed a sensitivity analysis using weighted GEE, implementing the inverse probability-weighted method to account for dropouts under the missing at random assumption. 29, 30 Because weighted GEE requires data to have a monotone missing data pattern, multiple imputation was used to impute the nearest missing observations postintervention using baseline characteristics and outcome measurement within treatment group.
31
All P values were 2-tailed, and significance was set at P<.05.
Results
We screened 1573 children and found that 506 were eligible. in the prior year, and 273 (68.3%) were prescribed a daily preventive medication. There were no significant differences in asthma morbidity, health care utilization, or preventive medication use at baseline assessment between groups. Table 2 shows study outcomes by group. For the primary outcome, we found that children in the SB-TEAM group had more SFDs per 2 weeks postintervention compared with children in the eUC group (11.6 vs 10.97; difference, 0.69; 95% CI, 0.15-1.22; P = .01). The secondary analysis using weighted GEE to accommodate missing data also showed significant treatment effects (difference, 0.73; 95% CI, 0.20-1.27). Children in the SB-TEAM group also had fewer symptom days, symptom nights, and days with limited activity compared with children in the eUC group. More children in the SB-TEAM group were prescribed a preventive asthma medication (91% vs 67%; odds ratio, 8.67; 95% CI, 4.19-17.95), and fewer had emergency department visits or hospitalizations for asthma (7% vs 15%, odds ratio, 0.52; 95% CI, 0.32-0.84) compared with children in the eUC group. In a longitudinal analysis of the primary outcome, findings were most pronounced at the final follow-up assessment, with a difference of 0.85 SFDs per 2 weeks between groups (95% CI, 0.10-1.59) and a significant treatmentby-time interaction (P =.02) (Figure 2) . Table 3 shows changes in FeNO level and quality of life from baseline assessment to the final follow-up. We found that children in the SB-TEAM group had a greater decline (ie, improvement) in FeNO level compared with children in the eUC group (mean difference, −5.54; 95% CI, −9.8 to −1.3); while quality of life improved for caregivers in both groups, there were no significant differences. There were no significant adverse events.
Importantly 
Discussion
We found that the SB-TEAM intervention yielded statistically significant improvements in outcomes among urban children with persistent asthma. Children receiving the intervention had more SFDs, fewer days with activity limitation, reduced airway inflammation, and fewer emergency department visits or hospitalizations for their asthma. The differences were comparable although slightly less than in our prior schoolbased work 32, 33 and were consistent with other communitybased asthma programs. [34] [35] [36] Importantly, this program was novel because it used telemedicine to enhance sustainability by linking children to PCPs. Further, the program was feasible and well accepted by families. The telemedicine model is one form of connected care that enhances access to medical services for traditionally underserved children 17, 37 and was an efficient way to link children to primary care and facilitate asthma assessment and treatment in this study. We were able to initiate telemedicine visits for almost all children in the SB-TEAM group, and most started DOT of preventive asthma medications at school. Importantly, models of care facilitated by telemedicine are now commonly used in both urban and rural settings, for both primary and specialty care. [38] [39] [40] [41] It is important to note that the role of the school nurses or health aides in this program is critical. This study took place in an impoverished school district. Most of the nurses covered multiple schools and had many competing demands on their time, yet children received their preventive medications almost every day they were in school. Nurses did not receive extra compensation for their efforts for this program. However, they frequently told us that they prefer to focus on preventive care rather than caring for children when they are experiencing an exacerbation. We suspect that the benefits related to supervised medication administration reach beyond simply assuring adherence to effective preventive medications and include the therapeutic relationships that were built between students and school nurses as well as the opportunities for ongoing monitoring and education.
Many of the children in this study lived in very difficult social situations and faced challenges that often accompany residing in impoverished communities. Most were in families with a single caregiver, many of whom reported depressive symptoms. Environmental tobacco smoke exposure was common. The struggles that families faced on a day-to-day basis were very real, and we acknowledge that an asthma care program can serve to relieve only a small part of these struggles. However, we were encouraged by the high participation and retention rates as well as high program satisfaction. We strongly believe that community partnerships can yield programs that are well accepted and lead to improved outcomes, even in the context of high rates of poverty and adversity.
Limitations
There are some potential limitations to this work. First, blinding of caregivers, children, and physicians was not possible. However, we performed blinded outcome assessments as well as objective measurements. Further, children in the eUC group may have experienced improved care simply through participating in the study, creating a conservative bias. While telemedicine is now used in many different settings to improve care, this study was done in a medium-sized city in elementary schools, and therefore, findings can only be generalized to similar settings and age groups. Only 82% of children in the SB-TEAM group received DOT at school; with more consistent protocol adherence, even more significant differences in outcomes may be observed.
Conclusions
We have consistently found that school-based programs can enhance care and improve outcomes for urban children with persistent asthma. The integration of telemedicine with schoolbased care represents one successful method to enhance access to guideline-based treatments and ensure appropriate primary care follow-up assessments. As we continue to work toward sustainability of these care models, it is important to consider resources available in each community to build collaborations that can be continued. Such models are most valuable if they reach the children at highest risk, fit logically into existing care systems, and ensure treatment can be delivered systematically and efficiently. In the future, sustained and enhanced funding for school-based programs will be critical, as care provided in schools can clearly improve outcomes for the children with greatest need. Our hope is that such care models will continue to expand nationwide to ensure the goals of therapy are met for all children with asthma to ultimately eliminate disparities in their health status. 
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24
It is increasingly recognized that asthma is a chronic disease characterized by inflammation in the 
35
Despite clear and well-developed guidelines for care, little has been done to assure implementation of 36 these guidelines. Many children in the US with persistent asthma symptoms do not receive preventive 37
medications. In addition, many children who are prescribed a preventive medication do not achieve 38 optimal control, at least in part due to poor adherence and lack of appropriate follow-up care. 
63
Telemedicine, a system that allows clinicians to provide assessment and consultation through remote 
71
there is reimbursement for telemedicine visits by local payers, making it a sustainable system of care.
72
Telemedicine is an efficient, cost-effective, and safe way of reaching patients and facilitating access to
73
care.
75
School-based programs represent a promising strategy for asthma management because of the 
110
Study Overview:
111
This proposed project aims to improve guideline-based asthma care using enhanced communciation and 112 screening tools, telemedicine and directly observed therapy of preventive medications in city schools.
113
This intervention is designed to overcome key barriers to guideline-based preventive asthma care 114 among minority, poor children in Rochester, NY. Web-based screening will be used to identify children
116
Children in the SB-TEAM group will receive a telemedicine asthma assessment in school and be 117 prescribed a daily preventive asthma medication to be taken through school-based directly observed 118 therapy. Follow-up telemedicine visits will be completed to make dose adjustments and treatment
119
revisions to optimize guideline based treatment. Intervention functions will be overseen by the asthma 120 coordinator,a registered nurse with extensive training in pediatric asthma, as well as Jill S. Halterman,
121
MD MPH T is to evaluate the use of the SB-
122
TEAM intervention for improving guideline based care, enhancing adherence to effective preventive 123 medications and at reducing morbidity among young urban children with asthma.
125
Study Design:
126
We propose a two-group randomized trial. Children in participating schools will be systematically 127 screened for asthma severity or control using the web-based system, and 400 eligible children will be our study team has been in place for many years, and all school district rules and regulations regarding 156 student confidentiality will be followed. Nurses, health aides, and study team personnel may also speak
157
with parents about the program during health fairs, parent orientation sessions, or other similar events.
158
We will also hang flyers at participating sites to allow interested parents to contact the study team 1. Inability to speak and understand English or Spanish (Spanish subjects will not be enrolled until
177
an amendment providing translated documents is approved). (*Parents unable to read will be eligible, and all instruments will be given verbally.) Based on our prior studies, we anticipate <10% of subjects to be excluded based on these criteria.
191 192
The recruitment goal for this study is to enroll 400 children using the Inclusion/Exclusion criteria stated coordinator to re-assess asthma symptoms at a later time during the screening and enrollment period.
212
Screening and enrollment will occur each year in a rolling fashion from late August through November to 213 enroll all children prior to the onset of peak winter season.
215
Prior to flagging/screening, the RSCD screening forms and medical-alert forms will be used to populate a 216 student registry into the secure web application. The school nurses may also add children into the 217 health status at his/her school (i.e. if the child has
218
. The school nurses may only view and edit 219 information in the web application for children at their school.
221
Screening process #1: The school nurse will log in the secure web screening application and complete a 222 223
indicators of asthma (asthma related visits to the nurse, rescue medication use in school, etc.). The 224 school nurse will record this information into a form of the web application to identify potentially 225 eligible children. When possible, the school nurse will also speak with the caregivers of the potentially 226 eligible children to con
227
If the child has persistent asthma symptoms, and therefore is eligible to participate in the study, the 228 school nurse will ask permission for the study team to call to introduce the study and schedule a home 229 visit. The flagging and screening information will be available to the asthma coordinator and the study 230 team via the web-based system (used in our prior SB-PACT study RSBR #32479).
232
Screening process #2: If school nurses are unable to complete the brief flagging form, the asthma 233 coordinator or study team member will review the RSCD screening forms, medical-alert forms, and
234
T or the study team 235 member 236 introduce the study, and schedule a home visit.
If the web application is down at the time of a screening, paper versions of the screening/eligibility form 239 will be used and the data will later be transcribed into the web application.
describe the program in detail 244 conduct a baseline assessment. The baseline evaluation will include: an assessment of asthma 245 symptoms, secondhand smoke exposure, home environment/triggers, standard family and health
246
history variables, and additional pertinent covariates. The baseline survey will be read aloud to 247 caregivers. We will obtain a saliva sample from each child to objectively measure environmental tobacco 248 smoke exposure through the biomarker cotinine, and we will also obtain exhaled nitric oxide (eNO)
249
measurements from each child in order to objectively measure airway inflammation. An asthma 250 symptom diary will be given to the caregiver for tracking of asthma symptoms throughout the school 
258
In instances where a caregiver states that their child (age ) is unable to provide assent to the 259 study (e.g., a child with autism), the assent form will be waived and the research assistant will document
261 262
In instances when the caregiver who provided consent is unavailable for follow-up, if a different
263
caregiver would prefer to respond to the follow-up assessments, the study will be described in detail
264
and verbal consent will be obtained over the telephone from the new caregiver for completion of the 265 follow-up survey. I , written consent will be obtained 266 from the new caregiver.
268
Participants will be given the option to allow for future contact for other research studies at the time of 269 consent. All participants who provided permission will be added to a future contact database dedicated 270 to childhood asthma research (RSRB #31010).
272
Randomization
273
Following completion of the baseline assessment, each child will be randomly assigned to either the SB-
274
TEAM group or the enhanced usual care (eUC) group. Randomization will be stratified by the use of a 275 preventive asthma medication, per parent report, at baseline. 200 children in both the SB-TEAM group 276 and the usual care group will be randomized. A permutated block design will be used to assure an equal 277 balance of children in each group over time. The randomization scheme will be independently 278 developed by the Biostatistics Center, and the interviewer will call the Study Coordinator who will
279
provide the subjec ID
281
A) SB-TEAM Group:
282
Once randomized, the study coordinator will use the web-based system or fax to send a symptom
283
report from the screening assessment and notification of enrollment in the study Revised 7. 
308
The telemedicine provider will deliver brief asthma 
319
Several clinicians routinely perform telemedicine visits as part of our current system, through 4 320 different practices that serve >60% of the children living in the city of Rochester. We will schedule
321
If there is no telemedicine
323
routinely available to perform visits; this scheduling system is well received and works very 324 efficiently.
326
All of the children in the study must have persistent asthma symptoms upon enrollment, and thus
327
warrant the use of a daily preventive asthma medication. 
367
Follow-Up Telemedicine Asthma Control Assessments and Medication Adjustments Follow-up
368 telemedicine assessments will occur twice during the study period. Follow-up visits will be 369 scheduled at school 4-6 weeks after initiating DOT, and again 4-6 weeks later. These visits will focus 370 on assessment of control, assessment of ongoing triggers or co-morbid conditions that might
371
interfere with an optimal response to treatment, and brief asthma education. The telemedicine 372 provider will also assess for any medication-related side effects (oral thrush, growth 373 monitoring). Guideline-based medication adjustments (or specialist referral, if appropriate) will be 374 recommended for children who continue to have persistent symptoms despite DOT in 375 school. I givers and 376 reports will be sent to the PCP.
378
We do not anticipate the opportunity to step-down therapy, since all children will have persistent 379 symptoms at the start of the trial and could benefit from several months of anti-inflammatory 380 therapy. A natural time for discontinuing or stepping-down therapy occurs at the end of the school Revised 7.11.17 year when the children will no longer be receiving medications through school. Two weeks prior to 382 the close of the study, we will notify both PCPs and families that children receiving preventive 383 medications at school no longer will receive medications through the study. PCPs will be directed to 384 provide ongoing medication management as needed.
386
The medications and spacers (if needed) B
387
on our prior research, we anticipate that most of the children will have some form of either private or 388 public health insurance, with most being insured by Medicaid. If a family does not have insurance or 389 insurance coverage status is uncertain, if there is an unexpected expense despite insurance coverage,
390
and when a family informs us they are unable to pay for the co-payment, we will pay for medications or 391 medication supplies (e.g., spacer, nebulizer mask, etc.). In all instances we will also assist the family in 392 getting insurance, help them to proactively plan for refills of medications, as well as link them with 393 services to help them afford co-payments.
394
Referrals to Additional Resources:
395
In the SB-TEAM, the telemedicine provider may also provide referrals to an asthma specialist,
396
Regional Community Asthma Network (RCAN), and New York State " Q line, as 397 appropriate.
399
B) Enhanced Usual Care (eUC) Group:
400
Similar to children in the SB-TEAM group, children in the enhanced usual care group will receive a 401 symptom assessment using national care guidelines, a recommendation for appropriate preventive 402 medications, and asthma education materials. After screening, baseline and randomization, we will 403 use the web-based screening and report system or fax PCP
404
with guideline-based recommendations for preventive care. We also will give all providers a 405 summary of the most current national guidelines. We will provide systematic feedback to the family 406 and providers at the same intervals as in the SB-TEAM
407
providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the
408
PCP. PCPs of children in the eUC group will assume responsibility for prescribing appropriate 409 medications during the study. In our prior studies, children in the eUC group improved over time,
410
thus creating a conservative bias.
412
Follow-Up Assessments
413
We will follow subjects prospectively through the end of the school year, which will vary from between 414 7-9 months depending on the timing of enrollment for each subject. The preliminary effectiveness of 415 the study will be assessed by telephone interviews with the caregivers, medical record review, and 416 review of school records including, absenteeism, school nurse records (e.g., visits to nurse, medication 417 use at school), and academic performance records ' 418 allocation, will conduct telephone calls with caregivers every other month following the initial baseline
419
to collect the follow-up data. At the end of the study year, a home visit will be conducted for the final 420 follow-up assessment at the end of the school year. While the intervention will only last 7-9 months, we 421 may follow subjects for up to 5 years post their enrollment into the study to collect additional outcome 422 measures. These measures may include medical chart review or additional survey assessments with the 423 primary caregiver. If additional surveys are conducted with the caregiver, we will request verbal 424 permission from the caregiver prior to collecting survey data.
426
Evaluations will be conducted with school health staff members who administered directly observed 427 therapy to children enrolled in the program and/or completed assessments using the web-based Revised 7.11.17 system. Paper surveys will be distributed prior to the end of each school year. Respondents will be asked 429 to complete the survey within a 2 week window and return via fax.
431
Healthcare providers whose patient(s) were enrolled in the program will also be asked to complete a 432 short evaluation asking for feedback on the process. These surveys will be administered on paper and 433 returned via fax and as a web-based survey with an email invitation.
435
We will also complete semi-structured interviews with participating school health staff and healthcare
436
providers to gather additional information on program acceptability.
438
Measures
439
The table below summarizes the outcome measures and covariates that will be collected for this study.
440
The 
446
This inflammation could be caused by many factors including colds, pollutant exposures, and asthma.
447
FeNO will be measured using the NIOX MINO® Airway Inflammation Monitor, an electrochemical hand-
448
held device that instantly analyzes exhaled air for NO concentration. Children will be asked to first fully 449 exhale and then to take a fast and deep inhalation through a disposable mouthpiece attached to the 450 device. Then, we will ask children to exhale slowly and steadily through the mouthpiece. If done 451 correctly, a reading will appear on the screen which will be recorded manually. FeNO will be measured 3 452 times, once at the baseline visit, at 4-month follow-up, and then again at the end of the school year.
453
Some children may have difficulty with this procedure; we will only include data for children who are 454 able to perform the procedure accurately.
456
Secondary Smoke Exposure: Saliva Sample Collection for Measurement of Cotinine:
457
Exposure to secondhand smoke will be assessed by both interview survey and cotinine measurements. 
472
Healthcare providers who complete an evaluation at the end of the program will be mailed a $5
473
Starbucks gift card to thank them for their time.
475
There may be some cost to participate in this study. Participants in the SB-TEAM group will be 476 responsible to purchase each medication and spacer that is dispensed as part of this study as well as any 477 fees associated with telemedicine visits (e.g., co-pays etc.) completed through the study (these are 478 479 participation in the study). Based on our prior work with this population, we anticipate that most of the 480 children will have some form of health insurance to cover the cost of visits and the medications with 481 minimal or no co-pay fee. In our prior studies we found that approximately 70% of families in the RCSD Revised 7.11.17
were insured with Medicaid which often eliminates co-pay fees for medications and care. If a child (in either group) does not have insurance, the study team will help the family secure health insurance. If a company will be responsible for the cost of all standard of care office visits and additional medications 488 prescribed by their PCP.
490
Data Storage and Confidentiality
491
To maintain the integrity, security, and confidentially of study data, the data will be maintained in a 492 secure and encrypted web-based database and/or a password protected database on a secure 493 university network drive. No subject data will be stored on the internal hard drives of any Strong Health 494 computers. After data validation and analysis, subject information will be de-identified. All consent 495 forms, paper surveys and additional correspondence will be stored in a locked filing cabinet in a locked 496 hallway or locked office, and will only be accessible by the study staff.
498
Baseline, follow-up, and chart review data will be entered into a password-protected Microsoft Access 
504
The screening data and PCP reports will be entered and/or generated through a secure password-
505
protected website created and managed by SophiTEC, a consulting and web design company that 
510
have their own unique login to the system. SophiTEC will manage and maintain study data backups. The 511 web application will utilize high grade encryption, and prior to any internet transmission, the webpage 512 will be encrypted. Timeout systems will also be in place to expire viewing data on the webpage.
514
Portions of the final assessments with caregivers, nurses, and healthcare providers may be tape 515 recorded. These recordings will be saved on a university network drive that is only accessible by study 516 personnel whom must use their NetID and password to access these tape recordings. Once the 517 recordings have been transcribed, they will be deleted from the network drive.
519
The Rochester City School District has partnered with the University of Rochester study team for this 520 521
outlined in the letter from Dr. Jeanette Silvers, Chief of Accountability for the Rochester City School
522
District. As deputies of the school district, the study team is granted permission to review limited 523 student information and contact families to inquire about their willingness to participate in the study.
525
Safety
526
This is not a drug investigational study since the effectiveness and safety of the FDA approved drugs that will be authorized/prescribed are already established and are not being tested. The intervention proposed should pose minimal risk to the children, since the medications that will be delivered at school
529
for the children in the intervention group are medications that are recommended as the standard of Revised 7.11.17
care for children with the degree of asthma symptom severity required for enrollment into the program
531
and are prescribed at the discretion of a pediatric health care provider. 
549
At home visits, research assistants will make efforts to protect subject privacy and confidentiality. The 550 research assistants will assure that the subject is comfortable answering questions and discussing the 551 study prior to completion of consent or any study measures If it is suspected that someone in the home 552 may cause serious harm to themselves or others, the study team will report these issues to the study 553 coordinator and the principal investigator who may be mandated to report these concerns to 554 appropriate authorities. There is also a risk that the study team may discover an unknown medical 555 condition. If this is to occur, we will refer the family to their PCP or another appropriate health care 556 professional for evaluation and treatment.
558
The study team will receive safety training yearly from key study personnel and safety plans for home 559 visits will be created (including traveling in pairs, safe words for emergency situations, and procedures
560
for notifying and updating coordinators about whereabouts). Additionally, these procedures are 561 outlined in a team training manual given to all employees. The study team will also receive cultural 562 awareness training from key study personnel prior to completing home visits. 
573
The research associates will be responsible for all data collected during the home assessments.
574
They will receive training from key study personnel regarding asthma terminology, symptoms, 575 medication understanding, and environmental assessment. They also will be trained by the senior 576 project coordinator on the use of equipment for cotinine measurements and the NIOX MINO ® 577 instrument for collection of exhaled nitric oxide. Revised 7.11.17
The senior project coordinator and project coordinators are all experienced in asthma terminology,
579
symptoms and other aspects of the illness and have extensive training in research methods. They will 580 oversee the data collection methods and all data will be reviewed by the study coordinators. Data forms collection errors. Through this training, staff will note any inconsistencies in parent reported data and 586 will discuss them with the parent at the time of the interview.
587
Key study personnel will perform all follow-up interviews and follow-up data management. These 588 data will be collected by the follow-up research associates who are independent from the research 589 associate recruiters, and thus we will be able to perform blinded assessments of outcomes. Our team,
590
including the principal investigator, senior project coordinator, and recruitment and follow-up project 591 coordinators, have a prior record of high-quality data collection and management. We tracked over 592 500 children in our prior school-based randomized trial, and completed follow-ups with 93% of subjects.
593
Treatment group assignment will not be included with any follow-up materials in order to ensure 594 blinding of the outcome assessment.
595
Once forms have been collected, errors that can be corrected over the telephone (legibility,
596
incorrect dates, etc.) will be done using telephone interviews. Forms will be keypunched into the 597 database using a double-entry system technique and checklists will be used to ensure that all data forms 
633
All records will be kept strictly confidential as required by the policies and procedures of the University
634
of Rochester where data are collected, processed, or reported.
636
Potential Benefits
637
Potential benefits for participants of the randomized trial exist for both groups of children (SB-TEAM and 638 eUC). The goal is for children in the SB-TEAM group to have improved symptom assessment, adherence 639 to preventive medications, and appropriate tailoring of therapy, thus they may experience less 640 morbidity from asthma. Although children in the eUC group will not be receiving medication through 641 school or telemedicine asthma visits, we will prompt their PCP to provide guideline based asthma care
642
including prescription of the appropriate preventive medications and will provide regular reminders to
643
PCP I
644
reduced morbidity for these children. Since the medications used in this study are safe and effective at 645 the doses administered, and are strongly recommended by the national asthma guidelines, we
646
anticipate that the intervention benefits will outweigh the minimal risk of participation.
648
Analysis
649
Sample Size:
650
This study is designed to have adequate power to detect the smallest clinically significant difference in 651 mean SFDs post-intervention between the intervention and enhanced usual care groups. Based on our
652
previous data, we estimate the pooled standard deviation of SFD at 2.8 and within-subject correlation at 653 0.3. Power was calculated for the intervention effect on SFD with at least two assessments for each 654 subject. We anticipate <15% attrition, as attrition was minimal (<10%) in the prior study, and therefore 655 plan to enroll 400 children. With a final sample of 336, we will have 90% power to detect a difference of 656 0.8 symptom-free days or greater per 2-wk. period. This difference is supported by our prior data, and 657 would justify continuing the intervention. There are more than 11,000 students in pre-k through 4 th 658 grade in the RCSD and at least 6,600 entering kindergarteners in a 3 year period. Conservatively
659
assuming an asthma prevalence of 9%, more than 1,584 students have asthma, and approximately ½ of 660 these students (792) have persistent asthma. In our prior study, we enrolled 74% of eligible subjects. A 661 conservative estimate would allow us to enroll 120 subjects/year (60%), which is more than adequate to 662 meet our sample size.
664
Primary Analysis:
665
The primary analysis of this study aims to assess the effectiveness of the SB-TEAM intervention in 666 reducing asthma morbidity (including symptom-free days post-intervention (follow-ups at 4 mo, 6mo 667 and final)as the primary outcome) compared to an enhanced usual care comparison group in school age 668 children with persistent asthma. We will follow subjects prospectively throughout the school year for 669 clinical outcomes (symptoms, asthma control, health care use), functional outcomes (absenteeism,
670
quality of life), and airway inflammation (FeNO). We will use graphical and numerical summaries to 671 describe the outcomes at each assessment point. If distributional assumptions associated with a 672 particular statistical procedure are violated, appropriate transformations will be made or non-subjects will be analyzed within the group to which they were assigned; minimal crossover is expected. 
683
To test for differences between the SB-TEAM and eUC groups on clinical and functional outcomes at the 684 primary time point, bivariate comparisons will be made using t-tests for continuous variables (number of 685 symptom-free days (SFD), symptom nights, rescue medication use, days absent, quality of life, FeNO,
686
and ACT scores), and chi-square tests for discrete variables (acute visits, hospitalizations). In addition,
687
the time-course of treatment response during the follow-up period will be evaluated using a linear 688 mixed model with the primary outcome, SFD at post-intervention, as the response, and treatment
689
condition, treatment by time interaction as independent variables. We will model the repeated 690 assessment post-intervention and assess post treatment effects as well as maintenance gain during the 691 period using appropriate linear contrasts. The analysis will be controlled for baseline symptoms, and
692
variables that are found to differentiate between groups at baseline. The treatment effect will be 693 regarded as fixed and the subjects will be modeled as random effect, with an appropriate variance 694 covariance structure specified. Secondary continuous outcomes will be analyzed in a similar manner.
695
Discrete outcomes will be analyzed by fitting Generalized Estimating Equation model. Appropriate link
696
functions and response probability distributions will be specified.
697
We will also consider whether certain process measures from our conceptual framework (adherence, 
704
confounders such as baseline symptoms will be included as covariates. Maximum Likelihood (ML) will 705 be used for estimation. Goodness-of-fit will be assessed in a two-level process. In the first level, the fit 706 of the unrestricted model will be tested using standard diagnostic measures for linear regression. In 
710
Approximation. We will use chi-square statistics for the structural invariance tests to determine effect 711 modifiers. These analyses will aid in our understanding of pathways by which SB-TEAM impacts
712
outcomes.
713
The primary analyses will be performed according to the intention-to-treat principle and will include all 714 randomized subjects. Substantial attention will be invested in participant retention; reasons for any 715 subject withdrawals that may occur will be carefully documented. Missing data patterns will be 716 examined by comparing subjects who discontinued with those who remained in the study. Inference 
